Key Takeaways
- • Blackstone, Carlyle Group, Hellman & Friedman, and Abu Dhabi Investment Authority are executing a secondary offering of 60 million Class A shares of Medline Inc., valuing the stake sale at approximately $3.1–$3.4 billion based on recent trading prices.
- • The three major private equity sponsors (Blackstone, Carlyle, and Hellman & Friedman) are each offering 23.3 million shares, while ADIA is offering 5.1 million shares, representing a structured partial liquidity event for the investor syndicate.
- • Medline completed a $7.2 billion initial public offering in 2024 following the consortium's $34 billion acquisition of the medical supplies company, establishing the foundation for this secondary offering.
- • Underwriters have been granted a 30-day option to purchase up to an additional 11.25 million shares, which could increase total offering size and proceeds if exercised.
- • The secondary offering demonstrates an early exit strategy for the PE sponsors, providing liquidity while maintaining significant ongoing ownership stakes in the diversified medical supplies manufacturer.
Summary
Medline Inc. announced an underwritten public offering of 60 million Class A common shares on behalf of major shareholder constituencies affiliated with Blackstone, Carlyle Group, Hellman & Friedman, and Abu Dhabi Investment Authority. The offering generates approximately $3.1–$3.4 billion in gross proceeds, with exact valuation dependent on final pricing relative to recent trading levels. The three primary private equity sponsors—Blackstone, Carlyle, and Hellman & Friedman—are each reducing their stakes by 23.3 million shares, while ADIA is offering 5.1 million shares, reflecting their decision to execute partial liquidity in advance of potential broader market conditions.
The transaction represents a structured secondary offering rather than primary capital raise for the company itself. Medline shares closed at $42.88 on the trading day prior to pricing, providing the baseline valuation framework for the offering. The underwriting syndicate has been granted a 30-day overallotment option permitting them to purchase up to an additional 11.25 million shares, which would expand total offering volume to approximately 71.25 million shares and increase gross proceeds if fully exercised.
This secondary offering follows Medline's $7.2 billion initial public offering in 2024, which itself represented the exit event for the acquisition consortium that purchased Medline Industries for approximately $34 billion. The Blackstone-Carlyle-Hellman & Friedman partnership took the medical supplies manufacturer public and has since maintained substantial ownership stakes. The current secondary offering allows these sponsors to reduce capital exposure selectively while retaining material long-term holdings in the diversified healthcare supplies company, balancing portfolio rebalancing against continued upside participation in Medline's operating performance.
The transaction represents a structured secondary offering rather than primary capital raise for the company itself. Medline shares closed at $42.88 on the trading day prior to pricing, providing the baseline valuation framework for the offering. The underwriting syndicate has been granted a 30-day overallotment option permitting them to purchase up to an additional 11.25 million shares, which would expand total offering volume to approximately 71.25 million shares and increase gross proceeds if fully exercised.
This secondary offering follows Medline's $7.2 billion initial public offering in 2024, which itself represented the exit event for the acquisition consortium that purchased Medline Industries for approximately $34 billion. The Blackstone-Carlyle-Hellman & Friedman partnership took the medical supplies manufacturer public and has since maintained substantial ownership stakes. The current secondary offering allows these sponsors to reduce capital exposure selectively while retaining material long-term holdings in the diversified healthcare supplies company, balancing portfolio rebalancing against continued upside participation in Medline's operating performance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.